Next Article in Journal
Evaluating the Impact of Intralipid Infusion on Pregnancy Outcomes in Infertility Treatments: A Retrospective Study
Previous Article in Journal
Exploring the Link Between Vaginal Delivery and Postpartum Dyspareunia: An Observational Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Assessing Thrombophilic Risk via Placental Histopathology: A Comparative Scoring Analysis

by
Viorela-Romina Murvai
1,2,
Anca Huniadi
3,
Radu Galiș
4,5,
Gelu Florin Murvai
6,
Brenda-Cristiana Bernad
7,8,
Carmen Ioana Marta
9,10,
Timea Claudia Ghitea
11,* and
Ioana Cristina Rotar
12,13
1
Doctoral School of Biological and Biomedical Sciences, University of Oradea, 1 University Street, 410087 Oradea, Romania
2
Department of Obstetrics and Gynecology, Emergency County Hospital Bihor, 65 Gheorghe Doja Street, 410169 Oradea, Romania
3
Department of Clinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 1 University Street, 410073 Oradea, Romania
4
Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 1 University Street, 410087 Oradea, Romania
5
Department of Neonatology, Emergency County Hospital Bihor, 65 Gheorghe Doja Street, 410169 Oradea, Romania
6
Surgery Department, Faculty of Medicine and Pharmacy, University of Oradea, 1 University Street, 410087 Oradea, Romania
7
Department of Neuroscience, “Victor Babes” University of Medicine and Pharmacy from Timișoara, 300041 Timișoara, Romania
8
Doctoral School, “Victor Babes” University of Medicine and Pharmacy from Timișoara, 300041 Timișoara, Romania
9
Clinic of Obstetrics and Gynecology, “Pius Brinzeu” County Clinical Emergency Hospital, 300723 Timișoara, Romania
10
Department of Obstetrics and Gynecology, Faculty of Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timișoara, Romania
11
Pharmacy Department, Faculty of Medicine and Pharmacy, University of Oradea, 1 University Street, 410087 Oradea, Romania
12
1st Department of Obstetrics and Gynecology, “Iuliu Haţieganu” University of Medicine and Pharmacy Cluj-Napoca, 400012 Cluj-Napoca, Romania
13
1st Clinics of Obstetrics and Gynecology Cluj-Napoca, Emergency County Clinical Hospital Cluj-Napoca, 400006 Cluj-Napoca, Romania
*
Author to whom correspondence should be addressed.
Reprod. Med. 2025, 6(4), 32; https://doi.org/10.3390/reprodmed6040032
Submission received: 12 October 2025 / Revised: 21 October 2025 / Accepted: 23 October 2025 / Published: 1 November 2025

Abstract

Introduction: Maternal thrombophilia is associated with numerous obstetric complications, often occurring without overt clinical manifestations during pregnancy. Histological evaluation of the placenta can provide valuable insights into the etiology of these complications. Objective: To compare the placental histopathological profile in pregnancies with thrombophilia versus physiological pregnancies and to develop a synthetic score capable of retrospectively indicating thrombophilic risk. Materials and Methods: A retrospective observational study was conducted on two groups (n = 80 thrombophilia, n = 31 control). Macroscopic and histopathological placental parameters were analyzed. A histological score (range 0–5 points) was constructed based on the presence of villous stasis, stromal fibrosis, infarction, acute atherosis, and intervillous thrombosis. Results: The mean histological score was significantly higher in the thrombophilia group (2.20 ± 1.4) compared to the control group (1.18 ± 1.1; p = 0.0011). A score ≥ 3 was present in 39.1% of thrombophilic cases versus 13.6% in controls. Regression analysis showed that only placental diameter was significantly correlated with the histological score (p = 0.0379). Conclusions: The proposed histological score may serve as a simple and effective tool for the indirect identification of potential thrombophilic risk in complicated pregnancies. Its validation in future studies could support its implementation in routine obstetric and histopathological practice.

1. Introduction

Thrombophilias, whether inherited or acquired, constitute a heterogeneous group of disorders characterized by increased coagulability and a predisposition to thrombotic events, which may compromise uteroplacental circulation and adversely affect pregnancy outcomes. These conditions are frequently associated with obstetric complications such as preeclampsia, intrauterine growth restriction (IUGR), abruptio placentae, and recurrent pregnancy loss, particularly in the second and third trimesters [1,2,3].
The clinical relevance of thrombophilia is further supported by its notable prevalence among women of reproductive age. Inherited thrombophilias are estimated to affect approximately 8–15% of pregnant women in European and North American populations, although prevalence varies depending on ethnicity, geographic region, and screening protocols [1,4,5]. Factor V Leiden remains the most common mutation, with heterozygous prevalence rates ranging from 3 to 8% among Caucasian pregnant women [1,3]. The Prothrombin G20210A mutation is found in 1–3% of women, while deficiencies of natural anticoagulants such as protein C, protein S, or antithrombin are less common (0.03–0.5%) but associated with a significantly increased thrombotic risk during pregnancy [4,6,7]. Despite this, many cases remain undiagnosed, as universal screening is not routinely recommended in the absence of clinical or obstetric risk factors [7,8]. This diagnostic gap highlights the need for adjunctive or indirect markers—such as placental histopathological changes—to retrospectively raise suspicion and guide postpartum management or future pregnancy care.
The placenta serves as a key interface between the maternal and fetal circulations, and its structural integrity is essential for a successful pregnancy. In thrombophilic pregnancies, impaired perfusion and microthrombotic events can lead to histological changes, including infarctions, intervillous thrombi, and delayed villous maturation. These lesions often remain subclinical and may be overlooked during routine gross examination, highlighting the value of systematic histopathological assessment in uncovering the underlying pathophysiological processes [9,10].
Among the most frequently reported lesions in thrombophilic pregnancies are intervillous thrombosis, placental infarctions, villous agglutination, villous stasis and immaturity, and degenerative vascular changes. These findings suggest a state of chronic placental dysfunction, although their diagnostic relevance remains insufficiently evaluated in standardized studies [11,12,13].
While individual placental lesions associated with thrombophilia are well described, their diagnostic significance remains poorly defined, and no standardized scoring system has been widely adopted. Most existing approaches rely on qualitative assessment and lack reproducible metrics to stratify thrombophilic risk. Therefore, a composite histopathological score could provide a more objective framework for assessing cumulative lesion burden, improving communication between pathologists and clinicians, and guiding further thrombophilia testing.
While several histopathological studies have described individual placental lesions associated with thrombophilia, standardized composite scoring systems are scarce. To date, most diagnostic approaches rely on qualitative assessments, without a unified tool to stratify risk based on lesion burden [14]. Our proposed histological score provides a simplified, additive model incorporating the most frequent lesions associated with thrombophilic pregnancies. By quantifying pathology in a reproducible format, it may enhance retrospective diagnosis and clinical decision-making.
The objectives of this study are to compare macroscopic and histopathological placental parameters between pregnancies with thrombophilia and those without complications; to identify histopathological features predictive of thrombophilia; to explore the potential of these features to form a clinically meaningful placental histological score. This study complements our previous work [15], which analyzed clinical and systemic parameters in the same patient population. The current analysis focuses specifically on placental histopathology and proposes a practical composite score for assessing thrombophilia-related lesions.

2. Materials and Methods

2.1. Study Design and Setting

This was a retrospective observational study conducted on two groups of placental samples collected from pregnancies delivered in a tertiary care maternity hospital. The study was approved by the local institutional ethics committee, and all procedures were conducted in accordance with the principles outlined in the Declaration of Helsinki. The study was carried out at “Emergency County Hospital Bihor” between September 2020 and September 2024. Ethical approval was granted by the Institutional Review Board, and all participants provided written informed consent before enrollment. The study protocol (approval no. 14146/15.06.2018) was reviewed and approved by the Institutional Ethics Committee of the University of Oradea. All participants provided written informed consent for the use of anonymized clinical and histopathologic data for research purposes, in accordance with institutional and national regulations and the Declaration of Helsinki.

2.2. Study Population

The study included two distinct cohorts:
1.
Thrombophilia group (TG)—placentas obtained from pregnancies diagnosed with hereditary thrombophilia with or without obstetrical complications (80 persons, 72.1%).
2.
Control group (CG)—placentas from pregnancies without known maternal pathology, delivering healthy newborns at term or late preterm (31 cases, 27.9%).
Inclusion criteria for both groups were the availability of complete placental examination (both macroscopic and histologic) and adequate clinical records. Exclusion criteria included multiple pregnancies, major fetal anomalies, intrauterine infections, or incomplete pathology data.
Sample size justification was based on preliminary power calculations estimating that a minimum of 30–34 subjects per group would allow detection of moderate effect sizes (Cohen’s d ≈ 0.7–0.8) with 80% power at α = 0.05. The final cohort exceeded this threshold for the thrombophilia group. Selection bias was minimized by applying uniform inclusion/exclusion criteria and blinding pathologists to clinical diagnosis during histopathologic evaluation.

2.3. Placental Examination

All placentas underwent standardized examination by the same team of pathologists. The pathologists performing the histopathological evaluations were blinded to the clinical diagnosis (thrombophilia vs. control group) to reduce potential bias in lesion identification and score assignment. Representative microphotographs (Figure 1) were taken directly from the analyzed cases and illustrate the main placental lesions assessed according to standardized histopathological criteria.
Macroscopic parameters included:
Placental weight (g),
Maximum diameter (cm),
Thickness (cm),
Umbilical cord length and insertion type.
Histopathologic features were evaluated according to standard criteria and included the presence or absence of the following lesions:
Intervillous thrombosis,
Villous agglutination,
Placental infarction,
Acute atherosis,
Stromal fibrosis,
Villous stasis,
Immature villi (villous maturation delay).
Histopathologic lesions were assessed according to standardized criteria. Although this study initially used descriptive terms, we have now aligned terminology with the Amsterdam Placental Workshop Group Consensus Statement (2016), categorizing findings as consistent with maternal vascular malperfusion (MVM) or fetal vascular malperfusion (FVM) where appropriate [16]. Lesions such as placental infarctions, decidual arteriopathy (acute atherosis), and accelerated villous maturation were classified under the category of MVM. Although features like avascular villi or thrombosed fetal vessels would indicate FVM, such findings were not identified in our cohort and thus were not included in Table 1.

2.4. Histologic Score Development

A synthetic histologic score (range 0–5) was developed by assigning one point for each of the following lesions when present:
Villous stasis
Stromal fibrosis
Intervillous thrombosis
Placental infarction
Acute atherosis
This score was calculated for each placenta, and its distribution was compared between the two groups. A cutoff value of ≥3 was tested for association with the thrombophilia group.
Although individual histopathologic variables did not reach conventional statistical significance, all demonstrated consistent directional trends toward higher prevalence in the thrombophilia group. Given the exploratory nature of this study and the interrelated pathophysiology of ischemic placental lesions, a simple unweighted additive model was used to capture the cumulative burden of pathology rather than the significance of single features. This approach is consistent with early validation stages of composite histologic scores.

2.5. Placental Histological Score for Suspected Thrombophilia

2.5.1. Concept

Based on the data obtained, we propose a simple additive score in which each histopathological lesion suggestive of thrombophilia is assigned a value of 1 point. The higher the score, the greater the probability that the placenta has been affected by ischemic or thrombotic changes characteristic of thrombophilia.

2.5.2. Parameters Included in the Score

Based on their increased frequency in the thrombophilia group and p-values approaching statistical significance, the following parameters are included in Table 2.

2.6. Statistical Analysis

All statistical analyses were performed using Python (v3.11; Python Software Foundation, Wilmington, DE, USA), SciPy (v1.12.0), and statsmodels (v0.14.1). Continuous variables were tested for normality and compared using the Student’s t-test or Mann–Whitney U test as appropriate. Categorical variables were analyzed with the Chi-square test or Fisher’s exact test. The multivariate analysis was performed using several tests (Pillai’s Trace, Wilks’ Lambda, Hotelling’s Trace, Roy’s Largest Root).
Correlations between the histologic score and continuous variables (placental weight, diameter, thickness, fetal weight, gestational age) were assessed using Pearson and Spearman coefficients. A linear regression model was built to assess predictors of the histologic score. A p-value < 0.05 was considered statistically significant.
For analyses involving multiple pairwise group comparisons, Bonferroni correction was applied to control for type I error inflation. When assumptions of normality were violated, non-parametric tests (Mann–Whitney U or Fisher’s exact) were used. All statistical analyses were two-tailed with α = 0.05 after adjustment.

3. Results

3.1. Study Cohort Characteristics

A total of 111 placentas were included in the final analysis. Of these, 80 were obtained from pregnancies complicated by confirmed maternal thrombophilia (study group), while 31 represented normal pregnancies without any documented maternal comorbidity (control group). All included cases had completed clinical records and placental pathology reports, with no exclusions for missing data or inadequate sampling.
The thrombophilia group included only hereditary forms. The control group was composed of singleton pregnancies that progressed uneventfully and resulted in healthy term or late-preterm neonates. The thrombophilia group included both term and late-preterm deliveries (34–36.9 weeks). Approximately 68% of cases in this group delivered before 37 weeks, often due to obstetric complications such as preeclampsia or fetal growth restriction.
The mean maternal age in the thrombophilia group was 35.8 ± 4.7 years, compared to 31.2 ± 3.9 years in the control group. Most participants were multiparous (68%) and of Caucasian ethnicity. The thrombophilia group included patients with confirmed hereditary conditions: Factor V Leiden mutation (42.5%), Prothrombin G20210A mutation (21.3%), MTHFR C677T mutation (18.8%), Protein S deficiency (10.0%), and Antithrombin deficiency (7.5%). Severity stratification (homozygous/heterozygous) was inconsistently reported in historical records and is listed as a study limitation.
The maternal age ranged between 21 and 46 years (mean 36.03 ± 2.8), and all women in the thrombophilia group had confirmed hereditary thrombophilia, though the specific genotypes were not stratified. The control group consisted of healthy, normotensive women with no personal or family history of thrombotic events or pregnancy complications. All neonates had 5 min Apgar scores ≥ 7, and no cases of fetal distress were recorded in the control group.
Multivariate analysis (Table 2) was performed using several tests (Pillai’s Trace, Wilks’ Lambda, Hotelling’s Trace, Roy’s Largest Root) to assess the combined effect of placental weight and newborn weight on the dependent variables.
The intercept was highly significant in all tests (p < 0.001), indicating that the overall model explains a substantial portion of the variance.
For placental weight, none of the multivariate tests were significant (p = 0.551), suggesting that it does not have a significant multivariate effect on the outcomes.
For newborn weight, all tests were highly significant (p < 0.01), with large effect sizes (e.g., Partial Eta Squared = 0.567 to 0.740), indicating a strong multivariate association with the dependent variables.
Table 3 was included to explore whether placental and neonatal morphometric parameters could explain the variability of histologic findings. Although placental weight did not contribute significantly, newborn weight showed a strong multivariate association with dependent outcomes, supporting the independence of histologic pathology from macroscopic metrics.

3.2. Sample Size Considerations

The size of the study groups was determined retrospectively, based on the availability of complete placental histopathological assessments during the study period. For exploratory analysis with continuous outcomes (e.g., histologic score), an a priori estimation suggested that a minimum of 30–34 cases per group would allow detection of moderate effect sizes (Cohen’s d ≈ 0.7–0.8) with a power of 80% and α = 0.05. The final cohort exceeded this requirement in the thrombophilia group, ensuring adequate statistical power for group comparisons.
Descriptive statistics for maternal and placental baseline parameters are summarized in Table 4.

3.3. Histopathologic Findings

The comparative histopathologic analysis between the thrombophilia group and the control group revealed a higher frequency of placental lesions among patients with thrombophilia. The most prevalent finding in this group was villous stasis, identified in 59.4% of cases, compared to 27.3% in the control group (p = 0.053), suggesting a near-significant difference (Figure 2).
Similarly, stromal fibrosis was more frequently observed in placentas from thrombophilic pregnancies (39.7% vs. 18.2%), with a p-value of 0.076. Although these two parameters did not reach conventional statistical significance (p < 0.05), their consistent association with the thrombophilia group indicates a relevant trend worth further investigation.
Massive perivillous fibrin deposition (MPVFD), a known feature associated with thrombophilic and immune-mediated placental injury, was not consistently reported in our cohort and was therefore not included in the current scoring model. We acknowledge this as a limitation of the retrospective design and recommend systematic assessment of fibrin deposition in future studies.
Other lesions, such as intervillous thrombosis (37.5% vs. 36.4%), placental infarctions (42.2% vs. 22.7%), and acute atherosis (42.2% vs. 13.6%) were also more frequent in the thrombophilia group, but did not demonstrate statistical significance in this cohort (all p > 0.05). Likewise, villous agglutination, vascular thrombi, and delayed villous maturation were variably distributed but showed no significant group differences.
These findings point toward a distinct histopathologic profile in thrombophilia, marked by a higher prevalence of ischemic and congestive lesions. Despite the lack of statistical significance in some cases, possibly due to sample size limitations, the consistent pattern observed may reflect an underlying placental dysfunction associated with prothrombotic states (Table 5). Terms such as ‘villous stasis’ and ‘boiled meat appearance’ were previously used descriptively by the examining pathologists. For clarity, we now interpret villous stasis as delayed villous maturation, and ‘boiled meat’ as a gross descriptor of homogenous parenchymal discoloration, often associated with infarction or perivillous fibrin deposition. These have been re-categorized according to consensus criteria.

3.4. Macroscopic Placental Parameters

Macroscopic analysis of placental dimensions revealed no statistically significant differences between the thrombophilia and control groups. The mean placental weight was 476.4 ± 135.5 g in the thrombophilia group and 470.2 ± 120.9 g in the control group (p = 0.8403). Similarly, the mean placental diameter did not differ significantly between the groups (16.88 ± 3.47 cm vs. 17.14 ± 1.96 cm, p = 0.6657). The mean placental thickness was also comparable (2.44 ± 0.99 cm vs. 2.27 ± 0.61 cm, p = 0.3678).
These findings suggest that, despite the higher frequency of histopathologic abnormalities in the thrombophilia group, macroscopic placental features alone are insufficient to distinguish between pathologic and non-pathologic placentas in this context. This reinforces the importance of histologic examination, particularly in cases with obstetrical complications but unremarkable gross findings (Table 6 and Figure 3).

3.5. Histologic Score Analysis

Based on the five most prevalent histopathologic lesions observed in the study cohort, a composite histologic score (range 0–5) was developed. Each of the following lesions contributed one point to the score when present: villous stasis, stromal fibrosis, intervillous thrombosis, placental infarction, and acute atherosis.
The threshold of ≥3 was selected post hoc based on its ability to discriminate between groups. In our cohort, this threshold yielded a sensitivity of 42.2% and specificity of 86.4% for identifying thrombophilic pregnancies. While not a definitive diagnostic cutoff, it may serve as a screening trigger for further clinical evaluation in the postpartum period.
The mean histologic score was significantly higher in the thrombophilia group compared to the control group (2.20 ± 1.4 vs. 1.18 ± 1.1, p = 0.0011), indicating a greater burden of histopathologic abnormalities in thrombophilic pregnancies.
Furthermore, a cutoff of ≥3 points was used to identify placentas with a high density of pathologic changes. This threshold was exceeded in 39.1% of placentas in the thrombophilia group, compared to only 13.6% in the control group (p = 0.015, Chi-square test), reinforcing the potential of this score as a screening tool for thrombophilia-related placental pathology. The threshold of ≥3 was chosen based on its ability to capture a cluster of multiple co-existing placental lesions. This value marked a significant inflection point in group differences and corresponds to the upper tertile of the score distribution. It also offered a pragmatic balance between sensitivity and specificity, identifying a subgroup with substantial histologic burden.
The cutoff of ≥3 was empirically determined as the upper tertile of the score distribution. Although sensitivity (42.2%) was modest, the specificity (86.4%) suggests good discriminative capacity for identifying placentas with a high burden of ischemic lesions. Future validation in larger cohorts will refine the optimal threshold.
Table 7 presents the comparative distribution of the histologic score, and Figure 4 illustrates its group-wise distribution.

3.6. Risk Threshold and Clinical Interpretation

To evaluate the practical utility of the histologic score, a threshold of ≥3 points was proposed as an indicator of increased risk for thrombophilia. This cutoff was chosen based on the observation that scores ≥ 3 occurred significantly more frequently in the thrombophilia group compared to the control group.
Application of this threshold to the study population yielded the following results:
Percentage of cases with histologic score ≥ 3:
Thrombophilia group: 42.5% (34 out of 80)
Control group: 9.6% (3 out of 31)
This marked difference supports the validity of the proposed threshold and suggests that a histologic score of ≥3 may serve as an indirect marker of placental pathology suggestive of underlying maternal thrombophilia, with potential relevance for retrospective screening and clinical evaluation (Figure 5).

3.7. Correlations Between Placental Histologic Score and Clinico-Morphological Parameters

To assess the potential impact of histopathological lesions on placental and fetal characteristics, correlations were analyzed between the placental histologic score and the following indicators: fetal weight, placental weight, placental diameter and thickness, and gestational age at birth.
The results of the Pearson correlation analysis in the thrombophilia group are presented in Table 8.
Of all the variables analyzed, only placental diameter showed a statistically significant, albeit weak and negative, correlation (r = −0.270, p = 0.0311), suggesting that a reduced placental diameter is associated with a higher histologic score and, implicitly, with a greater presence of histopathological lesions.
The remaining parameters, including fetal weight and gestational age, did not demonstrate significant correlations with the histologic score. This may indicate that such microscopic tissue changes are not always reflected in macroscopic placental measurements or in fetal growth parameters. These findings emphasize the subclinical and potentially insidious nature of placental lesions in thrombophilia, and support the importance of histopathological examination—even in the presence of apparently normal gross features.

3.8. Linear Regression

The multiple linear regression model failed to identify a combination of clinico-morphological variables that significantly predicted the histologic placental score. This result supports the conclusions drawn from the correlation analysis, indicating that histopathologic alterations are not directly mirrored by the clinical or macroscopic variables assessed. These findings reinforce the notion that histologic evaluation is essential for the detection of placental pathology in thrombophilic pregnancies, particularly when macroscopic findings are unremarkable (Table 9).
The only predictor that reached statistical significance (p < 0.05) was placental diameter, which showed a negative coefficient, further supporting the association between smaller placentas and the severity of histopathological lesions.
To explore potential associations between histologic placental changes and clinical or morphological parameters, Pearson correlation coefficients were calculated between the histologic score and the following continuous variables: fetal weight, placental weight, placental diameter, placental thickness, and gestational age (Table 6).
The analysis revealed that only placental diameter was significantly correlated with the histologic score (r = −0.270, p = 0.0311). All other variables showed weak or non-significant correlations, suggesting that macroscopic and clinical parameters do not reliably predict the extent of microscopic placental injury in thrombophilic pregnancies.
To better visualize these relationships, scatter plots were generated for each variable (Figure 6A–E). The inverse correlation between placental diameter and histologic score was the only one to show a consistent trend, supporting its potential use as an indirect marker of underlying placental pathology.

4. Discussion

In this study, we identified a distinct histopathological profile in placentas from pregnancies complicated by thrombophilia, including a higher prevalence of lesions suggestive of chronic ischemic and thrombotic injury. Although macroscopic placental parameters did not differ significantly between groups, histologic examination revealed more pronounced abnormalities in the thrombophilia group, which were captured effectively by the proposed histologic score [17,18,19,20].
Among the parameters evaluated, placental diameter emerged as the only variable significantly associated with the histologic score. Both the multiple linear regression model and Pearson correlation analysis indicated a statistically significant, though weak, negative relationship between diameter and histologic score (r = −0.270, p = 0.0311). This suggests that a smaller placental diameter may serve as an indirect marker of underlying histological damage. In contrast, fetal weight, placental weight, gestational age, and placental thickness showed no significant association with the severity of microscopic lesions [21,22,23,24,25].
Few standardized histologic scores have been proposed for thrombophilia-related placental pathology. Existing systems, such as those used for maternal vascular malperfusion (MVM) classification, focus on individual lesion severity rather than composite burden. Our score complements these by integrating five frequent lesions into a simple numeric framework, similar in concept to semi-quantitative indices in placental insufficiency studies [14,16,26].
Previous studies have described placental lesions such as infarctions, intervillous thrombi, and decidual vasculopathy in association with thrombophilia [12,17,27,28,29]. Redline et al. and others have reported a higher prevalence of these features in women with adverse pregnancy outcomes and hypercoagulable states. However, most studies have focused on individual lesions or lacked a unified scoring system. Our work extends these findings by integrating common histopathologic alterations into a simplified scoring model, potentially enhancing diagnostic yield and facilitating communication between obstetricians and pathologists. To enhance the clinical relevance of our findings, we retrospectively classified the histopathologic lesions based on the Amsterdam Consensus, which provides a robust framework for categorizing placental abnormalities by etiology. Most lesions identified in the thrombophilia group are consistent with maternal vascular malperfusion (MVM), further supporting the underlying prothrombotic state as a contributor to impaired uteroplacental circulation.
Previous studies have identified increased perivillous fibrin, particularly MPVFD, as a key marker of placental insufficiency in thrombophilia. While not incorporated in our current score due to reporting limitations, its role warrants further investigation and possible inclusion in revised scoring frameworks. Although our analysis was retrospective and did not include longitudinal follow-up, all patients diagnosed with hereditary thrombophilia received individualized counseling and hematologic evaluation. In most cases, postpartum thromboprophylaxis with low-molecular-weight heparin (LMWH) was recommended, and preventive anticoagulant therapy was planned for subsequent pregnancies based on risk stratification and obstetric history. Future prospective studies will aim to correlate histologic scores with therapeutic outcomes.
These findings reinforce the notion that macroscopic or clinical characteristics alone are insufficient to detect placental damage related to thrombophilia. The subclinical and often insidious nature of such changes highlights the importance of systematic histopathological evaluation [30], especially in pregnancies with adverse outcomes but unremarkable placental morphology [12,28]. The proposed score was not intended for diagnostic use but as an exploratory framework summarizing lesion co-occurrence. Further refinement and weighting based on multivariate regression or ROC analysis will be necessary for external validation.
The implementation of a standardized placental histologic score could influence clinical care by prompting retrospective thrombophilia screening in cases with high scores (≥3), even when not previously suspected during pregnancy. Identifying subclinical thrombophilia postpartum may allow for targeted thromboprophylaxis in subsequent pregnancies or non-obstetric settings. Additionally, in high-risk women, antenatal surveillance protocols could be intensified in future pregnancies, including earlier Doppler assessment, maternal coagulation profiling, and potential prophylactic anticoagulation based on interdisciplinary risk stratification [31,32,33]. The implementation of a simple additive histologic score, based on key lesions such as villous stasis, fibrosis, and infarction, allowed for a semi-quantitative assessment of placental damage. A threshold score of ≥3 points proved useful in differentiating between thrombophilic and physiological pregnancies, with potential applicability in retrospective diagnostic screening or postpartum risk stratification [34,35].
While placental diameter emerged as the only significantly correlated macroscopic feature with the histologic score, this was unexpected given the broader range of parameters typically associated with placental insufficiency (e.g., weight, fetal–placental ratio, cord abnormalities) [36]. The lack of statistical associations in other parameters may reflect the study’s limited sample size and the heterogeneity of thrombophilic disorders. This further emphasizes the potential value of microscopic over macroscopic examination in detecting subclinical placental pathology.
This study has several limitations that should be acknowledged. First, the sample size—particularly in the control group—was relatively small, which may have reduced the statistical power to detect more subtle differences. This imbalance resulted from the retrospective nature of the study and the requirement for comprehensive placental histopathological analysis, which is rarely performed in uncomplicated pregnancies). Furthermore, we applied appropriate statistical methods, including non-parametric and exact tests, to account for unequal group sizes. Second, the diagnosis of thrombophilia was not stratified by subtype (e.g., inherited vs. acquired, homozygous vs. heterozygous mutations), which may have introduced heterogeneity within the study group and diluted potential associations. Third, the retrospective design precluded the evaluation of dynamic or longitudinal changes during pregnancy and relied on available histological records and standardized reporting. Future studies should incorporate blinded assessments to strengthen objectivity. Additionally, the proposed histologic score was internally developed and applied to a single-center population, without external validation. As such, further studies on its generalizability to larger or more diverse cohorts are warranted [6,29,37].
This study has several limitations. First, as a single-center retrospective analysis, unmeasured confounding variables—such as maternal comorbidities, treatment regimens, or genetic heterogeneity—may have influenced histologic findings. Second, the unequal group sizes and predominance of hereditary thrombophilia limit generalizability to acquired forms and other populations. Third, absence of longitudinal follow-up restricts interpretation of causal relationships. Future multicenter prospective studies with larger and ethnically diverse cohorts are planned to externally validate the proposed histologic score and assess its predictive value for pregnancy outcomes.
Future prospective studies involving larger, well-characterized, and more diverse populations, including external validation cohorts, are needed to confirm the diagnostic and predictive value of the histologic score, to refine its clinical applicability, and to explore its potential role in ongoing pregnancies—particularly in conjunction with biomarkers and imaging-based assessments. From a clinical perspective, the histologic score offers a potential adjunct for postpartum risk stratification in pregnancies with adverse outcomes. By identifying women with placental signs suggestive of undiagnosed thrombophilia, this tool could support the initiation of thrombophilia workup, guide decisions regarding future pregnancy management, and reduce the recurrence of thrombo-embolic obstetric events. Its ease of application and reliance on standard histological assessments make it suitable for widespread use, pending validation.

5. Conclusions

This study highlights the diagnostic value of placental histopathological examination in pregnancies complicated by thrombophilia. Although macroscopic placental features did not differ significantly between groups, histological evaluation revealed a consistent pattern of lesions suggestive of ischemic and thrombotic injury. The development and application of a simple histologic score allowed for effective differentiation between thrombophilic and physiological pregnancies.
A score ≥ 3 was significantly more frequent in the thrombophilia group and may serve as an indirect marker for underlying maternal thrombotic pathology. While placental diameter showed a weak yet statistically significant inverse correlation with histologic severity, most clinical and morphological parameters failed to predict the extent of microscopic damage.
The findings underscore the subclinical nature of placental lesions in thrombophilia and support the integration of standardized histological scoring in routine obstetric and pathological practice. Future validation in larger, prospective cohorts is essential to confirm its utility and explore its potential role in postpartum screening, risk stratification, and management of thrombophilic patients.

Author Contributions

Conceptualization, V.-R.M. and T.C.G.; methodology, A.H.; software, R.G.; validation, G.F.M., T.C.G. and I.C.R.; formal analysis, T.C.G.; investigation, T.C.G. and B.-C.B.; resources, T.C.G.; data curation, T.C.G.; writing—original draft preparation, T.C.G.; writing—review and editing, T.C.G. and V.-R.M.; visualization, T.C.G. and C.I.M.; supervision, T.C.G.; project administration, T.C.G.; funding acquisition, T.C.G. All authors have read and agreed to the published version of the manuscript.

Funding

The APC was funded by the University of Oradea, Oradea, Romania No. 410068.

Institutional Review Board Statement

This study was conducted according to the Declaration of Helsinki and approved by the Ethics Committee of the University of Oradea (approval no. 14146/15.06.2018). Patients were recruited from the Department of Obstetrics and Gynecology, Emergency County Hospital Bihor, Oradea, Romania.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient(s) to publish this paper.

Data Availability Statement

The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. All data are stored in anonymized form within the institutional research archive at the University of Oradea.

Acknowledgments

The authors would like to thank the University of Oradea for supporting the payment of the invoice through an internal project.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Pabinger, I.; Vormittag, R. Thrombophilia and pregnancy outcomes. J. Thromb. Haemost. 2005, 3, 1603–1610. [Google Scholar] [CrossRef]
  2. Zotz, R.B.; Sucker, C.; Gerhardt, A. [Thrombophilia in pregnancy: Venous thromboembolism, fetal loss, preeclampsia, intrauterine growth restriction]. Hamostaseologie 2008, 28, 455–464. [Google Scholar]
  3. Sokol Karadjole, V.; D’Amato, A.; Milošević, M.; Herman, M.; Mikuš, M.; Laganà, A.S.; Chiantera, V.; Etrusco, A. Impact of Thrombophilic Polymorphisms in Antenatal Women on Perinatal Health: A Single-Center Prospective Study. J. Pers. Med. 2024, 14, 433. [Google Scholar] [CrossRef] [PubMed]
  4. Coppens, M. Understanding Limited Glove Use Among Pesticide Applicators: A Qualitative Study on Java Island, Indonesia; Knowledge, Technology and Innovation; Wageningen University: Wageningen, The Netherlands, 2016. [Google Scholar]
  5. Mast, A.E.; Ruf, W. Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy. J. Thromb. Haemost. 2022, 20, 1290–1300. [Google Scholar] [CrossRef]
  6. Rodger, M.A.; Walker, M.C.; Smith, G.N.; Wells, P.S.; Ramsay, T.; Langlois, N.J.; Carson, N.; Carrier, M.; Rennicks White, R.; Shachkina, S.; et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J. Thromb. Haemost. 2014, 12, 469–478. [Google Scholar] [CrossRef]
  7. Gurewitsch Allen, E.; Allen, R.H. Pathophysiologic Origins of Brachial Plexus Injury. Obstet. Gynecol. 2021, 137, 179–180. [Google Scholar] [CrossRef]
  8. Bates, S.M.; Greer, I.A.; Middeldorp, S.; Veenstra, D.L.; Prabulos, A.M.; Vandvik, P.O. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141, e691S–e736S. [Google Scholar] [CrossRef]
  9. Ciurea, E.L.; Berceanu, C.; Voicu, N.L.; Pirnoiu, D.; Berceanu, S.; Stepan, A.E. Morphological Survey of Placenta in Trombophilia Related Hypoperfusion of Maternal-Fetal Blood Flow. Curr. Health Sci. J. 2018, 44, 85–91. [Google Scholar] [CrossRef]
  10. Greer, I.A.; Aharon, A.; Brenner, B.; Gris, J.C. Coagulation and placenta-mediated complications. Rambam Maimonides Med. J. 2014, 5, e0034. [Google Scholar] [CrossRef] [PubMed]
  11. Pishghadam, M.; Haizler-Cohen, L.; Ngwa, J.S.; Yao, W.; Kapse, K.; Iqbal, S.N.; Limperopoulos, C.; Andescavage, N.N. Placental quantitative susceptibility mapping and T2* characteristics for predicting birth weight in healthy and high-risk pregnancies. Eur. Radiol. Exp. 2025, 9, 18. [Google Scholar] [CrossRef] [PubMed]
  12. Byrne, J.; Ranaei-Zamani, N.; Hutchinson, J.C.; Hillman, S. A retrospective analysis of placental histopathological findings in gestational diabetes mellitus (GDM). Placenta 2025, 162, 20–26. [Google Scholar] [CrossRef]
  13. Murvai, V.R.; Radu, C.-M.; Galiș, R.; Ghitea, T.C.; Tătaru-Copos, A.-F.; Vesa, A.-A.; Huniadi, A. The Relationship Between Thrombophilia and Modifications in First-Trimester Prenatal Screening Markers. Medicina 2025, 61, 318. [Google Scholar] [CrossRef] [PubMed]
  14. Gogia, N.; Machin, G.A. Maternal thrombophilias are associated with specific placental lesions. Pediatr. Dev. Pathol. 2008, 11, 424–429. [Google Scholar] [CrossRef]
  15. Murvai, V.-R.; Huniadi, A.; Galiș, R.; Murvai, G.F.; Ghitea, T.C.; Vesa, A.-A.; Rotar, I.C. Prothrombotic Genetic Mutations Are Associated with Sub-Clinical Placental Vascular Lesions: A Histopathological and Morphometric Study. Curr. Issues Mol. Biol. 2025, 47, 612. [Google Scholar] [CrossRef]
  16. Redline, R.W.; Ravishankar, S.; Bagby, C.M.; Saab, S.T.; Zarei, S. Four major patterns of placental injury: A stepwise guide for understanding and implementing the 2016 Amsterdam consensus. Mod. Pathol. 2021, 34, 1074–1092. [Google Scholar] [CrossRef] [PubMed]
  17. Mousa, H.A.; Alfirevic, Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum. Reprod. 2000, 15, 1830–1833. [Google Scholar] [CrossRef]
  18. Andreeva, T.; Komsa-Penkova, R.; Langari, A.; Krumova, S.; Golemanov, G.; Georgieva, G.B.; Taneva, S.G.; Giosheva, I.; Mihaylova, N.; Tchorbanov, A.; et al. Morphometric and Nanomechanical Features of Platelets from Women with Early Pregnancy Loss Provide New Evidence of the Impact of Inherited Thrombophilia. Int. J. Mol. Sci. 2021, 22, 7778. [Google Scholar] [CrossRef]
  19. Murvai, V.-R.; Galiș, R.; Macrea, C.-M.; Tărău-Copos, A.-F.; Goman, M.D.; Ghitea, T.C.; Huniadi, A. The Impact of Thrombophilia on Maternal and Neonatal Outcomes: A Multisystem Analysis of Clinical, Hematological, and Metabolic Parameters. J. Clin. Med. 2025, 14, 3665. [Google Scholar] [CrossRef]
  20. Endler, M.; Saltvedt, S.; Papadogiannakis, N. Macroscopic and histological characteristics of retained placenta: A prospectively collected case-control study. Placenta 2016, 41, 39–44. [Google Scholar] [CrossRef]
  21. Rawal, S.; Ray, S.; Sharma, N. Correlation Between Ultrasonographic Placental Thickness and Adverse Fetal and Neonatal Outcomes. Cureus 2024, 16, e56410. [Google Scholar] [CrossRef]
  22. Hamdy, A.; Ali, O.A. Role of measurement of placental thickness and diameter at the third trimester using two dimensional ultrasound in determination of low birth weight. Al-Azhar Int. Med. J. 2020, 1, 19–25. [Google Scholar] [CrossRef]
  23. Elmore, S.A.; Cochran, R.Z.; Bolon, B.; Lubeck, B.; Mahler, B.; Sabio, D.; Ward, J.M. Histology atlas of the developing mouse placenta. Toxicol. Pathol. 2022, 50, 60–117. [Google Scholar] [CrossRef]
  24. Benirschke, K.; Burton, G.J.; Baergen, R.N.; Benirschke, K.; Burton, G.J.; Baergen, R.N. Anatomy and pathology of the placental membranes. In Pathology of the Human Placenta; Springer: Berlin/Heidelberg, Germany, 2012; pp. 249–307. [Google Scholar]
  25. Pham, N.K. Placental Abruption: Clinical Indicators, Histological Findings, and Its Impact on Neonatal Health. Ph.D. Thesis, Université d’Ottawa/University of Ottawa, Ottawa, ON, Canada, 2025. [Google Scholar]
  26. Galis, R.; Trif, P.; Mudura, D.; Murvai, R.; Daina, L.G.; Szasz, F.; Negrini, R.; Hatos, A.; Gyarmati, B.F.; Daly, M.C.; et al. Preterm birth and stillbirth during COVID-19 pandemic in Bihor County/Romania. Front. Reprod. Health 2024, 6, 1286496. [Google Scholar] [CrossRef] [PubMed]
  27. Kovo, M.; Schreiber, L. Placental histopathology and pregnancy outcome in placental abruption. Thromb. Update 2021, 5, 100087. [Google Scholar] [CrossRef]
  28. Al Fahdi, M.; Riyami, N.A.; Ahmed, B. Placental histopathological abnormalities in adverse obstetric outcomes: A retrospective cross-sectional study at Sultan Qaboos University Hospital. BMC Women’s Health 2024, 24, 613. [Google Scholar] [CrossRef] [PubMed]
  29. Diggikar, S.; Galis, R.; Nagesh, K.; Pandita, A.; Ognean, M.L.; Rüdiger, M.; Mazela, J.; Kramer, B.W. Surfactant therapy—The conundrum of which infant should be given, when, which drug in what dose via which route of administration? Semin. Fetal Neonatal Med. 2024, 29, 101568. [Google Scholar] [CrossRef]
  30. Kemp, M.; Thomas, W. Antiphospholipid syndrome in obstetrics. Lupus 2018, 27, 28–31. [Google Scholar] [CrossRef]
  31. Dahiphale, S.M.; Dewani, D.; Dahiphale, J.M.; Agrawal, M.; Dave, A.; Pajai, S.; Jyotsna, G. Advances in Thromboprophylaxis for High-Risk Pregnancies: A Comprehensive Review of Current Strategies and Emerging Approaches. Cureus 2024, 16, e67758. [Google Scholar] [CrossRef]
  32. Stroia, C.M.; Ghitea, T.C.; Vrânceanu, M.; Mureșan, M.; Bimbo-Szuhai, E.; Pallag, C.R.; Pallag, A. Relationship between Vitamin D3 Deficiency, Metabolic Syndrome and VDR, GC, and CYP2R1 Gene Polymorphisms. Nutrients 2024, 16, 1272. [Google Scholar] [CrossRef]
  33. Tarcau, B.M.; Negru, A.; Ghitea, T.C.; Marian, E. Is There a Connection between Hyperhomocysteinemia and the Cardiometabolic Syndrome? Biomedicines 2024, 12, 1135. [Google Scholar] [CrossRef]
  34. Samfireag, M.; Potre, C.; Potre, O.; Tudor, R.; Hoinoiu, T.; Anghel, A. Approach to Thrombophilia in Pregnancy—A Narrative Review. Medicina 2022, 58, 692. [Google Scholar] [CrossRef] [PubMed]
  35. Mittal, N.; Byard, R.W.; Dahlstrom, J.E. A practical guide to placental examination for forensic pathologists. Forensic Sci. Med. Pathol. 2020, 16, 295–312. [Google Scholar] [CrossRef] [PubMed]
  36. Odendaal, H.; Geerts, L.; Wright, C.; Roberts, D.J.; Schubert, P.; Boyd, T.K.; Brink, L.; Nel, D. Association of Placental Histology with the Pulsatility Index of Fetal and Uteroplacental Vessels during Pregnancy and with Birthweight Z-Score. Med. Res. Arch. 2023, 11. [Google Scholar] [CrossRef] [PubMed]
  37. Mitranovici, M.I.; Chiorean, D.M.; Moraru, R.; Moraru, L.; Caravia, L.; Tiron, A.T.; Craina, M.; Cotoi, O.S. Understanding the Pathophysiology of Preeclampsia: Exploring the Role of Antiphospholipid Antibodies and Future Directions. J. Clin. Med. 2024, 13, 2668. [Google Scholar] [CrossRef]
Figure 1. Histopathologic features, including the presence or absence of the following lesions (A) Intervillous fibrosis, (B) Tenney Parker Modifications, (C) Villous stasis, (D) Placental infarction, and (E) Villous hypoplasia. (Histological evaluation was performed by a certified pathologist affiliated with our research team. Representative microphotographs were taken directly from the analyzed cases and illustrate the main placental lesions assessed according to standardized histopathological criteria.).
Figure 1. Histopathologic features, including the presence or absence of the following lesions (A) Intervillous fibrosis, (B) Tenney Parker Modifications, (C) Villous stasis, (D) Placental infarction, and (E) Villous hypoplasia. (Histological evaluation was performed by a certified pathologist affiliated with our research team. Representative microphotographs were taken directly from the analyzed cases and illustrate the main placental lesions assessed according to standardized histopathological criteria.).
Reprodmed 06 00032 g001
Figure 2. Prevalence of selected histopathologic placental lesions in thrombophilia and control groups. Villous stasis and stromal fibrosis were more frequent in the thrombophilia group, suggesting a trend toward ischemic and thrombotic placental injury.
Figure 2. Prevalence of selected histopathologic placental lesions in thrombophilia and control groups. Villous stasis and stromal fibrosis were more frequent in the thrombophilia group, suggesting a trend toward ischemic and thrombotic placental injury.
Reprodmed 06 00032 g002
Figure 3. Comparison of macroscopic placental parameters between thrombophilia and control groups. Boxplots illustrate the distribution of placental weight, diameter, and thickness, showing no statistically significant differences between groups. The rhombus represents exceptional cases.
Figure 3. Comparison of macroscopic placental parameters between thrombophilia and control groups. Boxplots illustrate the distribution of placental weight, diameter, and thickness, showing no statistically significant differences between groups. The rhombus represents exceptional cases.
Reprodmed 06 00032 g003
Figure 4. Distribution of histologic scores in thrombophilia and control groups. The histogram shows a shift toward higher scores in the thrombophilia group, suggesting a greater burden of histopathologic placental lesions. Yellow bars represent the thrombophilia group, orange bars represent the control group, and the brown overlay indicates overlapping values between the two groups. Higher scores denote a greater burden of ischemic and thrombotic placental lesions.
Figure 4. Distribution of histologic scores in thrombophilia and control groups. The histogram shows a shift toward higher scores in the thrombophilia group, suggesting a greater burden of histopathologic placental lesions. Yellow bars represent the thrombophilia group, orange bars represent the control group, and the brown overlay indicates overlapping values between the two groups. Higher scores denote a greater burden of ischemic and thrombotic placental lesions.
Reprodmed 06 00032 g004
Figure 5. Proportion of cases with high histologic score (≥3) in thrombophilia and control groups. A significantly greater proportion of placentas in the thrombophilia group reached the high-score threshold, supporting its potential as a screening marker for thrombophilic risk. Unlike our previous publication, which presented mean histologic scores, the present figure displays the proportion of cases with scores ≥ 3, emphasizing the frequency of placentas with extensive lesion clustering.
Figure 5. Proportion of cases with high histologic score (≥3) in thrombophilia and control groups. A significantly greater proportion of placentas in the thrombophilia group reached the high-score threshold, supporting its potential as a screening marker for thrombophilic risk. Unlike our previous publication, which presented mean histologic scores, the present figure displays the proportion of cases with scores ≥ 3, emphasizing the frequency of placentas with extensive lesion clustering.
Reprodmed 06 00032 g005
Figure 6. Correlation between histologic score and morphologic/clinical parameters (A) Fetal weight, (B) Placental weight, (C) Placental diameter (significant negative correlation, (D) Placental thickness, (E) Gestational age.
Figure 6. Correlation between histologic score and morphologic/clinical parameters (A) Fetal weight, (B) Placental weight, (C) Placental diameter (significant negative correlation, (D) Placental thickness, (E) Gestational age.
Reprodmed 06 00032 g006aReprodmed 06 00032 g006b
Table 1. Mapping of original histological terms to Amsterdam consensus classification and etiological category.
Table 1. Mapping of original histological terms to Amsterdam consensus classification and etiological category.
Original TermAmsterdam ClassificationCategory
Villous stasisDelayed villous maturationMVM
Stromal fibrosisStromal fibrosis (mild nonspecific)Other/MVM
InfarctionPlacental infarctionMVM
Acute atherosisDecidual vasculopathyMVM
Intervillous thrombosisIntervillous thrombi (if excessive: maternal malperfusion)MVM
MVM = maternal vascular malperfusion.
Table 2. Components of the placental histopathology score for thrombophilia assessment.
Table 2. Components of the placental histopathology score for thrombophilia assessment.
ParametersPoints
Villous stasis1
Stromal fibrosis1
Placental infarction1
Acute atherosis1
Intervillous thrombosis1
Total possible score: 0–5.
Table 3. Multivariate test results evaluating the effects of placental weight and newborn weight on dependent variables using weighted least squares regression.
Table 3. Multivariate test results evaluating the effects of placental weight and newborn weight on dependent variables using weighted least squares regression.
Multivariate Tests a,b
EffectValueFHypothesis dfError dfSig.Partial Eta Squared
InterceptPillai’s Trace0.975932.518 c2.00047.000<0.0010.975
Wilks’ Lambda0.025932.518 c2.00047.000<0.0010.975
Hotelling’s Trace39.682932.518 c2.00047.000<0.0010.975
Roy’s Largest Root39.682932.518 c2.00047.000<0.0010.975
Weight_placentaPillai’s Trace0.0250.604 c2.00047.0000.5510.025
Wilks’ Lambda0.9750.604 c2.00047.0000.5510.025
Hotelling’s Trace0.0260.604 c2.00047.0000.5510.025
Roy’s Largest Root0.0260.604 c2.00047.0000.5510.025
weight_new_bornPillai’s Trace1.1341.79570.00096.0000.0040.567
Wilks’ Lambda0.1582.038 c70.00094.000<0.0010.603
Hotelling’s Trace3.4902.29470.00092.000<0.0010.636
Roy’s Largest Root2.8393.894 d35.00048.000<0.0010.740
a Design: Intercept + Weight_placenta + weight_new_born, b Weighted Least Squares Regression—Weighted by Placenta_diameter, c Exact statistic, d The statistic is an upper bound on F that yields a lower bound on the significance level.
Table 4. Maternal-placental characteristics of the two groups.
Table 4. Maternal-placental characteristics of the two groups.
ParameterThrombophilia (n = 80)Control (n = 31)
Gestational age (wk)36.6 ± 2.637.1 ± 3.1
Fetal weight (g)2759.2 ± 695.82770.9 ± 630.4
Placental weight (g)476.4 ± 135.5470.2 ± 120.9
Placental diameter (cm)16.9 ± 3.517.1 ± 2.0
Placental thickness (cm)2.4 ± 1.02.3 ± 0.6
Table 5. Summarizes the distribution of histopathologic lesions across study groups.
Table 5. Summarizes the distribution of histopathologic lesions across study groups.
ParametersThrombophilia (72.1%)Control (28.9%)p
Villous stasis59.427.30.053
Stromal fibrosis39.718.20.076
Intervillous thrombosis37.536.40.186
Acute atherosis42.213.60.571
Placental infarction42.222.71.000
Chorionic vessel thrombosis12.513.61.000
Villous agglutination50.027.31.000
“Boiled meat” placental aspect31.713.61.000
Villous immaturity19.09.11.000
Table 6. Summarizes the macroscopic placental parameters across the two study groups.
Table 6. Summarizes the macroscopic placental parameters across the two study groups.
ParametersThrombophilia (Mean ± SD)Control (Mean ± SD)p
Placental weight (g)476.44 ± 135.52470.18 ± 120.920.8403
Placental diameter (cm)16.88 ± 3.4717.14 ± 0.66571.96
Placental thickness (cm)2.44 ± 0.992.27 ± 0.610.3678
Table 7. Histologic score by study group.
Table 7. Histologic score by study group.
GroupMean Score ± SDScore ≥ 3 (%)n
Thrombophilia2.20 ± 1.439.1% (25/64)80
Control1.18 ± 1.113.6% (3/22)31
Table 8. Pearson correlation between histologic score and clinical/morphological placental parameters in the thrombophilia group.
Table 8. Pearson correlation between histologic score and clinical/morphological placental parameters in the thrombophilia group.
ParametersPearson Coeficient (r)p
Fetal weight−0.0640.6137
Placental weight−0.1770.1619
Placental diameter−0.2700.0311
Placental thickness−0.1920.1356
Gestational age0.0300.8168
Table 9. Multiple linear regression model predicting placental histologic score based on clinico-morphological parameters (thrombophilia group).
Table 9. Multiple linear regression model predicting placental histologic score based on clinico-morphological parameters (thrombophilia group).
ParametersCoefficientStd. ErrortpCI 2.5%CI 97.5%
Intercept1.42863.33620.4280.6701−5.25478.1118
Fetal weight−0.00000.0005−0.1040.9174−0.00100.0009
Placental weight0.00000.00200.0100.9923−0.00400.0040
Placental diameter−0.13930.0655−2.1260.0379−0.2706−0.0080
Placental thickness−0.27320.1798−1.5200.1343−0.63340.0870
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Murvai, V.-R.; Huniadi, A.; Galiș, R.; Murvai, G.F.; Bernad, B.-C.; Marta, C.I.; Ghitea, T.C.; Rotar, I.C. Assessing Thrombophilic Risk via Placental Histopathology: A Comparative Scoring Analysis. Reprod. Med. 2025, 6, 32. https://doi.org/10.3390/reprodmed6040032

AMA Style

Murvai V-R, Huniadi A, Galiș R, Murvai GF, Bernad B-C, Marta CI, Ghitea TC, Rotar IC. Assessing Thrombophilic Risk via Placental Histopathology: A Comparative Scoring Analysis. Reproductive Medicine. 2025; 6(4):32. https://doi.org/10.3390/reprodmed6040032

Chicago/Turabian Style

Murvai, Viorela-Romina, Anca Huniadi, Radu Galiș, Gelu Florin Murvai, Brenda-Cristiana Bernad, Carmen Ioana Marta, Timea Claudia Ghitea, and Ioana Cristina Rotar. 2025. "Assessing Thrombophilic Risk via Placental Histopathology: A Comparative Scoring Analysis" Reproductive Medicine 6, no. 4: 32. https://doi.org/10.3390/reprodmed6040032

APA Style

Murvai, V.-R., Huniadi, A., Galiș, R., Murvai, G. F., Bernad, B.-C., Marta, C. I., Ghitea, T. C., & Rotar, I. C. (2025). Assessing Thrombophilic Risk via Placental Histopathology: A Comparative Scoring Analysis. Reproductive Medicine, 6(4), 32. https://doi.org/10.3390/reprodmed6040032

Article Metrics

Back to TopTop